Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3226116 | 0.98 | HTR2C (0.97) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| Butane SCHEMBL8573679 | 0.92 | HTR2C (0.85) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| Hydrochloric Acid SCHEMBL3213611 | 0.89 | HTR2C (0.79) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| SCHEMBL3552550 | 0.84 | HTR2C (0.72) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL1115308 | 0.82 | HTR2C (0.70) | HTR2CHTR2BADRA1DADRA1AADRA1B | |
| SCHEMBL20270447 | 0.79 | HTR2C (0.81) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| SCHEMBL31235894 | 0.79 | HTR2C (0.81) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| SCHEMBL3411611 | 0.78 | HTR2C (0.69) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| SCHEMBL537541 | 0.78 | HTR2C (1.00) | HTR2CHTR2BOPRD1KCNH2OPRK1 | |
| SCHEMBL34460267 | 0.78 | HTR2C (1.00) | HTR2CHTR2BOPRD1KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4825386-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| US-7507824-B2 | Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors | N.V. ORGANON (NL) | 2009-03-24 | — | — | US | claimed |
| EP-1232160-B1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS | ORGANON NV (NL) | 2008-06-18 | — | — | EP | claimed |
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2004-02-12 | — | — | US | claimed |
| US-6645973-B1 | Heterocyclic amines such as 1-carboxymethyl-4-(4-chlorophenyl) spiro(2H-1-benzopyran-2,4'-piperidine)hydrochloride used for therapy of nervous system disorders; Alzheimer's, Parkinson's and Huntington's disease | AKZO NOBEL (NL) | 2003-11-11 | — | — | US | claimed |
| EP-1232160-A1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS | Akzo Nobel N.V. (NL) | 2002-08-21 | — | — | EP | claimed |
| WO-2001036423-A1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE) DERIVATES AS GLYCINE TRANSPORT INHIBITORS | AKZO NOBEL N.V. (NL) | 2001-05-25 | — | — | WO | claimed |
| US-20240238254-A1 | PHARMACOLOGICAL INTERVENTION OF THE ARACHIDONIC ACID PATHWAY TO CURE AMYOTROPHIC LATERAL SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2022251254-A1 | PHARMACOLOGICAL INTERVENTION OF THE ARACHIDONIC ACID PATHWAY TO CURE AMYOTROPHIC LATERAL SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-2964613-B1 | H3 ANTAGONISTS CONTAINING PHENOXYPIPERIDINE CORE STRUCTURE | RICHTER GEDEON NYRT (HU) | 2018-07-18 | — | — | EP | disclosed |
| EP-2964613-A1 | H3 ANTAGONISTS CONTAINING PHENOXYPIPERIDINE CORE STRUCTURE | Richter Gedeon Nyrt. (HU) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014136075-A1 | H3 ANTAGONISTS CONTAINING PHENOXYPIPERIDINE CORE STRUCTURE | RICHTER GEDEON NYRT. (HU) | 2014-09-12 | — | — | WO | disclosed |
| EP-1675847-B1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-0860440-A1 | Sulfonamido substituted chromane derivatives with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| EP-0813414-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO. INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
| US-5652235-A | Method of using spiro piperidines to promote the release of growth hormone | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1995011029-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994013696-A1 | SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | SLC6A7, SLC1A2, SLC6A1 | HTR2C 585/4885HTR2B 820/4885OPRD1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.